The current study is aimed at bridging this knowledge gap by investigating the expression and association of selected CSC markers (CD44, CD133, and L1CAM) with an immune checkpoint inhibitor (PD-L1) in PNET and SPPN patients from the Pakistani population. The gene discussed is CD44; the disease is primitive neuroectodermal tumor.